history our business manufacturing expertise our sites board of directors corporate executive team corporate social responsibility code of conduct careers products products home special programs support services spc research & development r & d home pipeline clinical trials partnering scientific publications netter 1 study investor relations ir home news & events stock information corporate governance financial information shareholder services press room press room home news press releases conferences & events photo gallery nuclear medicine about nuclear medicine diagnostics therapy glossary contact search for englishfran aisitalianoespa ol our ambition at advanced accelerator applications is to turn scientific findings into life enhancing applications . advanced accelerator applications announces presentations on lutathera netter 1 phase iii and neobomb1 at eanm october 2016 aaa today announced that data from the pivotal netter 1 phase iii study investigating the treatment of lutathera lutetium lu 177 dotatate in patients with somatostatin receptor positive midgut neuroendocrine tumors midgut nets and preclinical oncology studies with neobomb1 a novel grpr antagonist will be presented at the 29th annual congress of the european association of nuclear medicine eanm october 15 19 in barcelona spain . read more a worldwide presence aaa operates in belgium canada france germany israel italy the netherlands poland portugal spain switzerland uk and usa while its distribution network covers more than 30 countries . please point to any of the locations to pull up specific details about each facility . read more products advanced accelerator applications aaa develops produces and commercializes molecular nuclear medicine diagnostic and therapeutic products in the fields of oncology cancer neurology cardiology and infectious & inflammatory diseases . read more pipeline our key product candidates in clinical developement are lu dotatate lutathera ga68 dotatate toc somakit and annexin v 128 . lu dotatate is a molecular nuclear therapy product candidate . read more molecular nuclear medicine making personalised treatment a reality . aaa is a european leader in the production and commercialization of pet positron emission tomography and spect single photon emission tomography radiopharmaceuticals and is able to produce and deliver both commercial drugs and research products . discover our documentary about molecular nuclear medicine and cancer . molecular nuclear medicine with a 22 documentary from the history of radioactivity and cancer to the most modern theragnostic techniques . you will understand how spect and pet work and how radio metabolic therapy can treat cancer . search for homepage contact careers site map disclaimer 2014 20 advanced accelerator applications all rights reserved